#Nonalcoholic Steatohepatitis Treatment Market trends | Explore Tumblr posts and blogs

kritikarehani · 4 years ago

Text

Nonalcoholic Steatohepatitis (NASH) 2030 | Nonalcoholic Steatohepatitis Market Outlook 2030 | DelveInsight

Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is an advanced form of nonalcoholic fatty liver disease (NAFLD), caused by the buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis.

NASH usually comes under the category of silent diseases that has very few or no symptoms typically because it does not cause any symptoms until it is too late. In the early period, patients did not complain about anything specific. Even with the advancing fibrosis, the disease may not have any specific problems. However, in the later stages, patients may start developing some non-specific symptoms.

DelveInsight's "Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Nonalcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the Nonalcoholic Steatohepatitis (NASH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Nonalcoholic Steatohepatitis (NASH) market report provides current treatment practices, emerging drugs, Nonalcoholic Steatohepatitis (NASH) market share of the individual therapies, current and forecasted Nonalcoholic Steatohepatitis (NASH) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Nonalcoholic Steatohepatitis (NASH) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geographies covered are:

The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan

Request for sample pages of our report: https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market

Nonalcoholic Steatohepatitis (NASH) Disease Understanding and Treatment Algorithm

The classification of fibrosis stages of NASH is as follows: No Fibrosis (F0), NASH Fibrosis (F1–F3), and NASH Cirrhosis (F4).

According to various studies, such as Schuppan et al. (2018), Singh et al. (2014), and others, NASH has been defined to keep progressing from early stages (F0 and F1) to advanced stages (F2–F4) over time. The development of NASH with cirrhosis increases the risk of NASH Decompensated Cirrhosis and ultimately to death.

The DelveInsight Nonalcoholic Steatohepatitis (NASH) market report gives a thorough understanding of the Nonalcoholic Steatohepatitis (NASH) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Nonalcoholic Steatohepatitis (NASH).

Treatment

It covers the details of conventional and current medical therapies available in the Nonalcoholic Steatohepatitis (NASH) market for the treatment of the condition. It also provides Nonalcoholic Steatohepatitis (NASH) treatment algorithms and guidelines in the United States, Europe, and Japan.

Nonalcoholic Steatohepatitis (NASH) Epidemiology

The Nonalcoholic Steatohepatitis epidemiology division provide insights about historical and current Nonalcoholic Steatohepatitis (NASH) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

• Of all the prevalent cases of NAFLD in the 7MM, approximately 19% of the population fulfilled the criteria for NASH. These cases are expected to increase throughout the study period [2018–2030].

• We estimate the highest prevalence of NASH in the United States, accounting close to 50% of the total prevalent cases, followed by Japan.

Download free sample pages of our report.

Nonalcoholic Steatohepatitis (NASH) Drug Chapters

Due to the unmet need for an approved therapy for the treatment of NASH, several companies have shifted their focus toward the development of targeted drugs with a novel mechanism of action.

Key players in the market of NASH are Genfit, Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Gilead Sciences, Allergan (Tobira Therapeutics), Galmed Pharmaceuticals, Bristol-Myers Squibb, Cirius Therapeutics, Galectin Therapeutics, Immuron, NGM Biopharmaceuticals, Can-Fite BioPharma, Akcea Therapeutics, Oramed Pharmaceuticals, Ascletis, Terns Pharmaceuticals, Enyo Pharma, and others.

We expect that the launch of emerging therapies will fill the void treatment areas shortly. The targeted therapies will have stronger penetration than the off-label therapies, and the market is expected to reach billions.

Nonalcoholic Steatohepatitis (NASH) Market Outlook

The market for the treatment of Nonalcoholic Steatohepatitis (NASH) is likely to experience significant annual growth over the 2018–2030 study period, as major-market sales are expected to increase by 2030. OCA is expected to grab maximum market share, owing to its development to target all stages of NASH (F1–F4), and with the increasing demand for therapies to treat the advanced stage of NASH, i.e., cirrhosis.

The treatment of NASH depends on the stage of the disease. Currently, there is no approved therapy for the treatment of NASH, yet doctors prescribe certain off-label drugs (supportive therapies) for its management. Lifestyle modifications are, however, the first line of treatment. Lifestyle modifications include going for weight loss combined with an active exercise program along with a planned diet.

Medications are then prescribed in the later stages when lifestyle modifications do not produce significant results. Insulin-sensitizing agents are prescribed in some instances; however, metformin produced good results but temporarily, due to which it is not recommended much. Pioglitazone is suggested in select cases for patients already who have Type II diabetes.

The Nonalcoholic Steatohepatitis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Nonalcoholic Steatohepatitis (NASH) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

According to DelveInsight, Nonalcoholic Steatohepatitis (NASH) market in 7MM is expected to change in the study period 2017-2030.

#NASH market #NASH market trends #NASH market share #NASH market size #NASH market outlook #NASH treatment market

0 notes

marketreportsupdates · 4 years ago

Text

Nonalcoholic Steatohepatitis Market Size, Growth rate, Industry Challenges and Opportunities to 2027

The Global Nonalcoholic Steatohepatitis market research report provides an insightful analysis of the current market, along with a futuristic perspective on the growth of the market. The aim of this report is to provide beneficial information to clients, market players, and stakeholders and assist them in making fruitful business decisions according to the information provided. The report offers valuable insights into the market size, market share, revenue, sales volume, and CAGR. The information offered by the report gives an idea about the scope, potential, and profitability of the market.

The recent COVID-19 pandemic has drastically changed the dynamics of the market and resulted in an economic slowdown. The report covers an impact analysis of the pandemic on the overall market. It also includes the changes in demands and factors that might influence the growth or restrain the growth in a post-COVID-19 scenario. The report also consists of the present and future impact of COVID-19 on the market.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1111

Key participants include Genfit, Intercept Pharmaceuticals, Gilead Sciences, Galmed Pharmaceuticals, Inventiva, Allergan and Tobira Therapeutics. Gilead Sciences is a key player in the NASH market. With a global presence in more than 35 countries, the company offers drugs including Selonsertib, Cilofexor and Firsocostat for the treatment of NASH.

The forecast estimation states the global Nonalcoholic Steatohepatitis market is expected to dominate the economic sphere of the world with significant growth in the coming years. The growth is boosted by a change in demand patterns, rapidly developing infrastructure, technological advancements, and product advancements. The current and emerging trends are expected to shape up the industry and help in gaining a strong foothold in the global market to contribute to the revenue generation.

The Global Nonalcoholic Steatohepatitis market is further analyzed on the basis of key companies operating in the business sphere and major geographical regions where the market has a substantial size and growth rate.

Disease Cause Outlook (Revenue, USD Million; 2018-2026)

Hypertension

Heart Disease

High Blood Lipid

Type 2 Diabetes

Obesity

Drug Type Outlook (Revenue, USD Million; 2018-2026)

Vitamin E & Pioglitazone

Ocaliva

Elafibranor

Selonsertib

Cenicriviroc

Others

To read more about the report @ https://www.reportsanddata.com/report-detail/non-alcoholic-steatohepatitis-nash-market

End-user Outlook (Revenue, USD Million; 2018-2026)

Hospitals

Clinics

Homecare settings

Zonal Partition of the Market: North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa.

The report covers extensive analysis of market segments that are anticipated to lead by the end of the forecast period (2020-2027). The report puts a special emphasis on the upstream raw materials, downstream buyers, industrial chain analysis, technological and product advancements, and production and manufacturing capacities of the Nonalcoholic Steatohepatitis market. Moreover, the report provides an in-depth analysis of the core segments of the market by analysis of the applications, types, consumption patterns, market drivers and restraints, and challenges to be faced in the market.

The research study focuses on the emerging development patterns and manufacturing processes anticipated to boost the growth of the market. It also includes extensive profiles of prominent contenders of the industry and provides a complete analysis inclusive of their market share, market size, production capacity, sales and distribution network, import/export activity, and product portfolios.

Major objectives of the Global Nonalcoholic Steatohepatitis Report:

· Analysis and forecast estimation of the Global Nonalcoholic Steatohepatitis Market based on the market segmentation into types, applications, and regions

· Analysis of micro and macroeconomic factors affecting the global Nonalcoholic Steatohepatitis market

· Valuable insight into the major drivers, limitations, opportunities, and challenges faced by the global Nonalcoholic Steatohepatitis market and its players

· In-depth analysis of the prominent contenders along with their business strategies and expansion plans

· Strategic recommendations to the established companies as well as new entrants to assist in the formulation of investment plans

· Comprehensive analysis of the competitive landscape of the Nonalcoholic Steatohepatitis industry

To summarize, the report provides a better understanding to the reader about the Nonalcoholic Steatohepatitis industry by offering a detailed explanation of the competitive landscape, industry environment, market projections, growth driving and restraining factors, limitations, entry barriers, and opportunities. The report also covers the regulatory framework, investment opportunities, and other growth driving factors. The report allows the reader to gather insightful information about each segment of the market and provides a historical, present, and prospective outlook of the market.

Thank you for reading our report. To know more about the report or for any queries regarding customization, please connect with us. Our team will provide excellent assistance and make sure the report is tailored to meet your requirements.

Browse Related Reports:-

Purified Human Proteins Market Analysis, Top Players, Demand, Industry Challenges and Opportunities to 2027

Genome Editing Market Size, Demand, Shares, growth and Forecasts to 2027

John W

Head of Business Development

40 Wall St. 28th floor New York City

NY 10005 United States

Direct Line: +1-212-710-1370

0 notes

statzyreportsmarketresearch · 4 years ago

Text

(COVID-19 Version) Global Nonalcoholic Steatohepatitis (NASH) Market

The report forecast global Nonalcoholic Steatohepatitis (NASH) market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2025 due to coronavirus situation. The report offers detailed coverage of Nonalcoholic Steatohepatitis (NASH) industry and main market trends with impact of coronavirus. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Nonalcoholic Steatohepatitis (NASH) by geography. The report splits the market size, by volume and value, on the basis of application type and geography. First, this report covers the present status and the future prospects of the global Nonalcoholic Steatohepatitis (NASH) market for 2015-2024. And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru]. At the same time, we classify Nonalcoholic Steatohepatitis (NASH) according to the type, application by geography. More importantly, the report includes major countries market based on the type and application. Finally, the report provides detailed profile and data information analysis of leading Nonalcoholic Steatohepatitis (NASH) company.

Key Content of Chapters as follows (Including and can be customized) : Part 1: Market Overview, Development, and Segment by Type, Application & Region Part 2: Company information, Sales, Cost, Margin etc. Part 3: Global Market by company, Type, Application & Geography Part 4: Asia-Pacific Market by Type, Application & Geography Part 5: Europe Market by Type, Application & Geography Part 6: North America Market by Type, Application & Geography Part 7: South America Market by Type, Application & Geography Part 8: Middle East & Africa Market by Type, Application & Geography Part 9: Market Features Part 10: Investment Opportunity Part 11: Conclusion

Market Segment as follows: By Region Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia] Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland] North America[United States, Canada, Mexico] Middle East & Africa[GCC, North Africa, South Africa] South America[Brazil, Argentina, Columbia, Chile, Peru] Key Companies Boehringer Ingelheim Cerenis Therapeutics Connexios Life Sciences Genfit Islet Sciences Nimbus Therapeutics Verva Pharmaceuticals Viking Therapeutics Astazeneca Plc Galmed Pharmaceuticals GENFIT SA Gilead Science Novo Nordisk Immuron Intercepts Pharmaceuticals Enzo Biochem Tobira Therapeutics Market by Type Weight Loss Treatment Insulin-Sensitizing Agents Lipid-Lowering Drugs Antioxidants Others Market by Application Hospitals Clinics Research Institute Others

for sample report please visit: https://www.statzyreports.com/report.php?reportnumber=SR151841&reportnames=COVID-19-Version-Global-Nonalcoholic-Steatohepatitis-NASH-Market-Status-2015-2019-and-Forecast-2020-2025-by-Region-C-Product-Type--6-End-Use

Phone Number (IN) - +918484035727

(US) - +1415-871-0483

Email Address Email : [email protected]

Email : [email protected]

#Global Nonalcoholic #Steatohepatitis (NASH) Market

0 notes

expertofmarketinsights-blog · 6 years ago

Text

Nonalcoholic Steatohepatitis Treatment Market Growth Factors 2018 – 2026

Nonalcoholic steatohepatitis treatment (NASH) is a syndrome which causes liver damage in non-alcoholic patients. It develops most often in patients with at least one factors such as dyslipidemia, obesity, and glucose intolerance. NASH pathogenesis is not clearly understood however is considered to be linked with insulin resistance. It is diagnosed with the help of blood tests, imaging tests, and sometimes liver biopsy. Treatment of the NASH includes elimination of causes and risk factors such as reducing fat level in the body. NASH is also considered to be one of the chief causes of cirrhosis which can lead to complete liver failure.

Download PDF Brochure of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-pdf/2279

Market Dynamics

Obesity, high blood pressure and cholesterol level, type 2 diabetes and metabolic syndrome are the major cause of the NASH onset. Increasing prevalence of these conditions worldwide is expected to drive the global nonalcoholic steatohepatitis treatment market growth during the forecast period. According to the International Diabetes Federation 2017 data, approximately 425 million people were suffering from diabetes in the world and 82 million cases were in the South East Asia region which is expected to reach 151 million by 2045.

However, diagnosis of the NASH can be difficult to catch in an early stage and can take years before patients show any sort of symptoms which is a major factor hampering the nonalcoholic steatohepatitis treatment market.

Nonalcoholic steatohepatitis (NASH) is a form of nonalcoholic fatty liver disease (NAFLD) in which a person have hepatitis and inflammation of the liver, and can cause liver damage. NASH can lead to complications, such as cirrhosis and liver cancer. Patients with NASH have high chance of mortality due to liver-related causes such as liver failure.

Lifestyle modification, including change in diet and exercise, is the basic therapy recommended for nonalcoholic fatty liver disease. However, in some cases lifestyle modification is difficult to achieve and to sustain, and therefore required other treatments including medicine.

Currently available drugs for the treatment of NAFLD were historically been given for other indications. For instance, Orlistat, a gut lipase inhibitor, is indicated for decrease in the dietary fats absorption. According to the National Center for Biotechnology Information (NCBI) 2017 study, Orlistat has been approved for treatment of obesity and is available over the counter in the U.S. for weight loss. Orlistat-mediated weight loss is related with reduction in hepatic steatosis.

The global nonalcoholic steatohepatitis treatment market size was valued at US$ 1,119.9 million in 2017 (based on existing approved therapies anti-diabetics, vitamins, dietary supplements, and others) and is expected to witness a CAGR of 42.7% over the forecast period (2018 – 2026).

Nonalcoholic Steatohepatitis Treatment Market - Regional Insights

On the basis of region, the global nonalcoholic steatohepatitis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America and Europe nonalcoholic steatohepatitis treatment market is expected to foresee significant growth owing to increasing incidence of obesity and fatty liver.

According to the National Health and Nutrition Examination Survey, the proportion of NAFLD among chronic liver diseases increased from 47% to 75% between 1988 and 2008 in the U.S. According to the National Institutes of Health, in 2015 nearly 3 to 12% of adults in the U.S. were suffering from NASH. The major reason for this increase was an increase in metabolic risk factors. According to the Journal of Hepatology, in 2013, approximately one-third of adults exhibit a pattern of NAFLD in Europe.

Nonalcoholic Steatohepatitis Treatment Market - Competitive Landscape

Key players operating in the global nonalcoholic steatohepatitis treatment market include AstraZeneca Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc.

Request For Customization Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-customization/2279

Detailed Segmentation:

Global Nonalcoholic Steatohepatitis Treatment Market, By Drug:

Cenicriviroc

Elafibranor

Ocaliva (Obeticholic Acid)

Selonsertib

Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1–206–701–6702

Email: [email protected]

#Nonalcoholic Steatohepatitis Treatment Market #Nonalcoholic Steatohepatitis Treatment Market size #Nonalcoholic Steatohepatitis Treatment Market trends #Nonalcoholic Steatohepatitis Treatment Market outlook

0 notes

jesse-pinkman123 · 2 years ago

Link

The report examines the Nonalcoholic Steatohepatitis Treatment market with respect to the industry trends, growth rate, prospects, drivers, restraints, threats, and lucrative opportunities, by means of distinguishing the high-growth segments of the market through the various stakeholders.

#Nonalcoholic Steatohepatitis Treatment Market Share #Nonalcoholic Steatohepatitis Treatment Market Outlook

0 notes

myabhijitr · 6 years ago

Text

Nonalcoholic Steatohepatitis Treatment Market – Global Industry Outlook, and Analysis, 2018-2026

Get Free Request Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2279

Rising incidence of nonalcoholic steatohepatitis and strong product pipeline are expected to drive the nonalcoholic steatohepatitis treatment market revenue

Nonalcoholic steatohepatitis has become one of the most common liver-related health problems. The condition has been linked to an unhealthy diet and weight gain, but it can also be observed in non-obese individuals. Increasing prevalence of insulin resistance, and obesity is expected to fuel the nonalcoholic steatohepatitis treatment market during the forecast period.

According to an article published in Lancet, globally, prevalence of overweight and obesity combined has risen by 27.5% for adults between 1980 and 2013. According to the National Health and Nutrition Examination Survey (NHANES) 2014 data, in U.S. the percentage of obesity is higher in women, i.e. 40%, than in men, 35%.

Most therapies for NASH are in early- or mid-stage development and some are in late-stage studies. Multiple companies are focused on the development of drugs. In April 2018, AstraZeneca has licensed IONIS-AZ6-2.5-L, which has been renamed to AZD2693. The newly licensed drug is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis. In 2016 Bristol-Myers Squibb acquired rights for a NASH program from Osaka, Japan-based Nitto Denko Corporation.

Despite the significant burden to the public health system, there are no FDA-approved specifically tailored drugs for nonalcoholic steatohepatitis treatment. Therefore, there is an immense need for effective treatment to manage the complex pathophysiologic processes of NASH. Numerous medications targeting different stages and molecular events in the disease process are currently in the pipeline, increasing the promise of successful treatment of NASH in the future.

Download Free PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2279

Nonalcoholic Steatohepatitis Treatment Market - Competitive Landscape

About Coherent Market Insights:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]

#nonalcoholic steatohepatitis treatment market #nonalcoholic steatohepatitis treatment market size #nonalcoholic steatohepatitis treatment market share

0 notes

ihealthcareanalyst · 8 years ago

Text

Global Nonalcoholic Steatohepatitis Treatment Market USD 19.8 Billion by 2025

Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is one of the causes of fatty liver, occurring when fat is deposited (steatosis) in the liver due to causes other than excessive alcohol use.

According to a market research report Nonalcoholic Steatohepatitis Treatment Market 2015-2025 published by iHealthcareAnalyst, Inc., the global nonalcoholic steatohepatitis treatment market is estimated to reach USD 19.5 Billion in 2025, expanding at a CAGR of 10.0% from 2016 to 2025.

Visit the Nonalcoholic Steatohepatitis Treatment Market 2015-2025 report at https://www.ihealthcareanalyst.com/report/nonalcoholic-steatohepatitis-treatment-market/

The global nonalcoholic steatohepatitis treatment market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020).

The global nonalcoholic steatohepatitis treatment market segmentation is based on phase III drugs in pipeline (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor). The global nonalcoholic steatohepatitis treatment market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

1. Drug Type 1.1 Phase III Drugs 1.1.1 Aramchol (Arachidyl Amido Cholanoic Acid) 1.1.2 Elafibranor 1.1.3 Obeticholic Acid (OCA) 1.1.4 Saroglitazar 1.2 Phase I and II Drugs

2. Geography (Region, Country) 2.1 North America (U.S., Canada) 2.2 Latin America (Brazil, Mexico, Rest of LA) 2.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 2.4 Asia Pacific (Japan, China, India, Rest of APAC) 2.5 Rest of the World

3. Company Profiles 3.1 AstraZeneca plc 3.2 Conatus Pharmaceuticals 3.3 Galmed Pharmaceuticals 3.4 Genfit Sa 3.5 Gilead Sciences Inc. 3.6 Immuron Ltd. 3.7 Intercept Pharmaceuticals Inc. 3.8 Tobira Therapeutics Inc. 3.9 Zydus Cadila

About Us

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: [email protected] Website: https://www.ihealthcareanalyst.com

- https://www.ihealthcareanalyst.com/global-nonalcoholic-steatohepatitis-treatment-market/

0 notes

rohinic123-blog · 5 years ago

Text

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size will Observe Substantial Growth by 2027

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Introduction

According to the report, the global non-alcoholic steatohepatitis (NASH) biomarkers market was valued at ~US$ 300 Mn in 2018 and is projected to expand at a high CAGR during the forecast period. Non-alcoholic steatohepatitis is an advanced stage of non-alcoholic fatty liver disease (NAFLD), which arises when the excess fat accumulation causes inflammation and damage leading to liver scarring. A biomarker is the most effective diagnosis tool for measuring the biological state and is termed as an indicator for measuring normal biological processes and pathogenic process in the body. Biomarker tools available for diagnosing NASH condition are known as non-invasive tools and few of them are serum biomarkers, biomarker panels, fibrosis biomarkers, Imaging Biomarkers, and others. The others category includes gene biomarkers and oxidative stress biomarkers. Rise in research & development is likely to offer promising biomarkers for the accurate diagnosis of NASH condition.

Planning To Lay Down Future Strategy? Request Brochure Of Non-alcoholic Steatohepatitis (NASH) Biomarkers Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18650

The global non-alcoholic steatohepatitis (NASH) biomarkers market is driven by the increase in prevalence of NAFLD & NASH disease; large unmet needs in terms of disease epidemiology and available diagnostic and therapeutic tools; rise in demand for non-invasive diagnostic methods; increase in geriatric population; growing incidences of obesity and type 2 diabetes; awareness about diagnostic tools; and shift of government focus toward providing better healthcare facilities. These factors are likely to propel the non-alcoholic steatohepatitis (NASH) biomarkers market across the globe.

North America dominated the global non-alcoholic steatohepatitis (NASH) biomarkers market in 2018 and the trend is anticipated to continue during the forecast period. The region’s dominance can be ascribed to the availability of innovative non-invasive biomarkers, presence of key players, growing NASH patient population, technological advancements, awareness about the diagnosis procedure, increase in obesity and type 2 diabetes, and surge in awareness about various causes leading to fatty liver. However, limited accuracy of NASH diagnostic tools such as biomarkers in proper diagnosis are likely to restrain the global non-alcoholic steatohepatitis (NASH) biomarkers market during the forecast period.

To Obtain All-Inclusive Information On Forecast Analysis Of Non-alcoholic Steatohepatitis (NASH) Biomarkers Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=18650

Rise in Prevalence of NAFLD and NASH to Propel Global Market

The incidence rate of non-alcoholic liver diseases has increased significantly. Patients with obesity and type 2 diabetes are estimated to be more prone to NAFLD and other liver diseases. This is expected to augment the prevalence of non-alcoholic liver diseases. Changes in lifestyle and high pollution levels are anticipated to boost the prevalence of nonalcoholic liver diseases. This, in turn, is estimated to drive the NASH biomarkers market in the near future.

As per research, worldwide prevalence of NAFLD was estimated to be 25.2%, and NASH was estimated to be in a range of 1.5% to 6.45% respectively in 2019. NASH prevalence across the globe is expected to grow by 63% by 2030.

Increase in Prevalence of Obesity & Type 2 Diabetes to Drive Global Market

Obesity and Type 2 diabetes are the two major lifestyle diseases, which are likely to increase the prevalence of NASH and NAFLD condition. As per NCBI, prevalence of obesity has tripled since 1980 and nearly one-third of the world population is categorized as overweight or obese. According to the Centers for Disease Control and Prevention (CDC), in the U.S., prevalence of obesity was estimated to be 42.4% from 2017 to 2018. The prevalence of severe obesity in the adults in the U.S. was estimated around 9.2% in 2017–2018. Growing incidence of obesity across the population is likely to increase the NASH incidence in the population. People suffering from type 2 diabetes are on verge of developing NAFLD and further into NASH condition. As per the International Diabetes Federation, in 2019, approximately, 463 million adults were suffering from diabetes and the patient population is likely to rise by 700 million by 2045. This statistics is likely to boost the risk of developing NASH condition. Around 70% to 80% of the obese are estimated to suffer from NAFLD, while around 55% of patients with type 2 diabetes are prone to NAFLD.

Request For Covid19 Impact Analysis –

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=18650

Rise in Demand for Non-invasive Diagnostics to Drive Global Market

Liver biopsies are the gold standard in diagnosis and monitoring of NASH in the absence of any alternative diagnostic tools. Liver biopsy is a painful procedure for most patients; bleeding occurs in most cases. The mortality rate associated with liver biopsy stands at one in 10,000. Furthermore, liver biopsies are not entirely accurate, for the diagnosis of the NASH condition. These drive the need of developing non-invasive diagnostic techniques, which includes novel biomarkers for diagnosis and routine monitoring of NASH. Various key players in the pharmaceutical and biotechnology industries are investing in this field. The NASH therapeutics market is projected to reach US$ 35 Bn to US$ 40 Bn by 2024. Companies such as Allergan, Novo Nordisk, and Genfit, and Intercept are investing significantly in the NASH therapeutics market. This is likely to benefit companies offering innovative and emerging noninvasive diagnostic tools such as imaging biomarkers, and gene biomarkers.

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Prominent Regions

In terms of region, the global non-alcoholic steatohepatitis (NASH) biomarkers market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global non-alcoholic steatohepatitis (NASH) biomarkers market in 2018, followed by Europe. North America accounted for major share of the global non-alcoholic steatohepatitis (NASH) biomarkers market in 2018. This can be attributed to the large patient pool suffering from NASH and NAFLD indication, along with increasing liver diseases. Rise in prevalence of obesity and Type 2 diabetes, rise in demand of non-invasive diagnostic tool such as biomarkers, and adoption of emerging and innovative biomarkers are few major attributable factors for the NASH biomarkers market.

Technological advancements leading to the development of innovative emerging biomarkers is another major factor expected to augment the market in North America. The non-alcoholic steatohepatitis (NASH) biomarkers market in Latin America is likely to expand at a highest CAGR from 2019 to 2027. This can be attributed to rise in prevalence of NASH indication in the population in Latin America, rising liver disease, awareness about diagnosis of NASH indication, increase in healthcare expenditure, and large patient population suffering from type 2 diabetes and obesity and other metabolic syndrome.

Mergers by Key Players to Drive Global Market

The global non-alcoholic steatohepatitis (NASH) biomarkers market is consolidated in terms of number of players. The market is dominated by key players with strong geographic presence and strong product offerings. Leading players operating in the global non-alcoholic steatohepatitis (NASH) biomarkers market include Biopredictive, Quest Diagnostics, Exalenz Bioscience Ltd, GENFIT, Siemens Healthineers, ONE WAY LIVER, S.L, Prometheus Laboratories Inc., and Gilead Sciences, Inc. Merger & acquisition is a major strategy adopted by key players offering NASH biomarkers for non-alcoholic steatohepatitis condition for faster and continuous diagnosis of the condition. For instance, in November 2019, Galectin Therapeutics entered into agreement with Siemens Healthineers, which would enable Siemens Healthineers to utilize Galectin’s Phase 2 NASH-CX clinical trial for supporting the regulatory filing of its ADVIA Centaur Enhanced Liver Fibrosis (ELF) test. This would also allow Siemens Healthineers to use ADVIA Centaur ELF test data from Galectin Therapeutics Phase 3 NASH belapectin clinical trial in the treatment of NASH liver cirrhosis.

More Trending Reports by Transparency Market Research –

Spinal Trauma Devices Market -

https://www.prnewswire.com/news-releases/spinal-trauma-devices-market-to-touch-us4-7-billion-by-2023--says-tmr-300819355.html

Erectile Dysfunction Treatment Devices Market –

https://www.biospace.com/article/-erectile-dysfunction-treatment-devices-market-lessening-stigma-and-more-awareness-likely-to-drive-the-growth-tmr/

0 notes

kritikarehani · 5 years ago

Text

Nonalcoholic Steatohepatitis Market Insights, Epidemiology and Market Forecast-2028

DelveInsight’s ‘Nonalcoholic Steatohepatitis Market Insights, Epidemiology and Market Forecast-2028’ NASH Market report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the NASH market trends in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current nonalcoholic steatohepatitis treatment practices, emerging drugs, NASH market share of the individual therapies, current and forecasted market size of Nonalcoholic Steatohepatitis from 2016 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

The United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2016-2028

Request for Sample Pages

Nonalcoholic Steatohepatitis - Disease Understanding and Treatment Algorithm

Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is an advanced form of non-alcoholic fatty liver disease (NAFLD), caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis. Nonalcoholic Steatohepatitis usually comes under the category of silent diseases that has very few or no symptoms typically because it doesn’t cause any symptoms until it’s too late.

The classification of fibrosis stages of NASH is as follows: No Fibrosis (F0), NASH Fibrosis (F1, F2 and F3), and NASH Cirrhosis (F4). According to various studies, such as Schuppan D et.al. [2019], Siddharth Singh et.al. [2014], and others NASH has been defined to keep progressing from early stages (F0 and F1) to advanced stages (F2, F3, F4) over time. The development of NASH with cirrhosis increases the risk of NASH Decompensated Cirrhosis and ultimately to death.

The DelveInsight Nonalcoholic Steatohepatitis market report gives the thorough understanding of the NASH by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for NASH in the US, Europe, and Japan.

Nonalcoholic Steatohepatitis Epidemiology

The NASH Epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalent Cases of Non-Alcoholic Fatty Liver Disease, Total Prevalent cases of Nonalcoholic Steatohepatitis and Nonalcoholic Steatohepatitis Segmentation by Fibrosis Stage] scenario of Nonalcoholic Steatohepatitis in the 7MM countries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2028.

According to DelveInsight, increase in obesity, diabetes population will significantly increase the prevalent cases of NAFLD with the CAGR of 1.02% for the study period i.e. 2016-2028 in the 7MM. Of all the prevalent cases of NAFLD in the 7MM, approximately 19% of the population fulfilled the criteria for NASH. These cases are expected to increase throughout the study period [2016-2028], reaching nearly 47 million cases in 2028. We estimate highest prevalence of NASH in the United States, accounting for almost 50% of the total prevalent cases, followed by Japan. On the other hand, it is assessed that among the European countries, Germany accounted for the highest prevalent population, followed by Italy. Among all the 7MM countries, Spain had the lowest prevalent population.

Request for Sample Pages

Nonalcoholic Steatohepatitis Drug Chapters

This segment of the Nonalcoholic Steatohepatitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

NASH treatment depends on the stage of the disease. Currently, there is no approved therapy for the treatment of NASH, yet doctors prescribe certain off-label drugs (supportive therapies) for its management. Lifestyle modifications are however the first line treatment. Lifestyle modifications include going for weight loss combined with active exercise program. Diet is also planned accordingly.

Medications are then prescribed in the later stages when lifestyle modifications do not produce significant results. Insulin sensitizing agents are prescribed in certain cases, however, metformin produced good results but on a temporary basis, due to which it is not recommended much. Pioglitazone is recommended in selected cases for patients already suffering with type II diabetes.

Vitamin E produces very significant results and is prescribed in most cases. Vitamin E is a first line therapy only for patients without diabetes. It is not recommended for patients with diabetes, NASH cirrhosis or cryptogenic cirrhosis. Statins are also prescribed in cases when a person has the cardiovascular risk associated with NASH. Statins are not recommended until histologic data are available.

Detailed chapters of upcoming therapies such as Elafibranor (Genfit), OCA (Intercept Pharmaceuticals), Selonsertib (Gilead Sciences), Cenicriviroc (Allergan- Tobira), GS-9674 (Gilead Sciences), Aramchol_005 (Galmed), MSDC-0602K (Cirius Therapeutics), Emricasan (Conatus Pharmaceuticals), and others which are expected to launch during the nonalcoholic steatohepatitis market forecast period [2019-2028] have also been covered in the report.

Nonalcoholic Steatohepatitis Market Outlook

The Nonalcoholic Steatohepatitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Nonalcoholic Steatohepatitis market treatment will experience significant annual growth over the 2016-2028 study period, as major-market sales increase up to USD 30,096.1 million by 2028. As the number of effective treatments for the NASH increases during the forecast period, the supportive therapies (off-label) market share will start to decrease, from a peak of 100% in 2016 to ~11% in 2028. Elafibranor (Genfit) will be the first drug for the NASH treatment which will targeting the NASH Fibrosis (F1, F2 & F3) patients and Obeticholic acid (OCA; Intercept Pharmaceutical) will give competition to Elafibranor. Intercept’s OCA is expected to grab maximum nonalcoholic steatohepatitis market share, owing to its development to target all stages of NASH (F1 to F4), except F0 and with the increasing demand for therapies to treat advanced stage of NASH, i.e. cirrhosis.

Nonalcoholic Steatohepatitis Drugs Uptake

This section focusses on the rate of uptake of the potential NASH drugs recently launched in the market or will get launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The leading companies in NASH market are Genfit, Intercept Pharmaceuticals, Gilead Sciences, Allergan (Tobira Therapeutics), Galmed Pharmaceuticals, Bristol-Myers Squibb, Cirius Therapeutics, Conatus Pharmaceuticals, Galectin Therapeutics, Immuron, NGM Biopharmaceuticals, Akcea Therapeutics and others. We expect that the launch of emerging therapies will fill the treatment void in the near future. The targeted therapies will have stronger penetration than the off-label therapies and the market is expected to reach in billions.

Intercept’s Obeticholic Acid (OCA) is expected to grab maximum market share, owing to its development to target all stages of NASH (F1 to F4), except F0 and with the increasing demand for therapies to treat advanced stage of NASH, i.e. cirrhosis, this drug is expected to influence the market size with a greater percentage.

Apart from OCA, Selonsertib, and Emricasan, two other drugs which are expected to enter the NASH therapeutic market targeting cirrhosis stage of NASH, include GR-MD-02 by Galectin Therapeutics and Immuron’s IMM-124E. Both of these drugs are expected will grab a significant proportion in the market size.

Furthermore, the expected launch of drugs, which are in the Phase II stage of clinical development shall significantly drive the market size forward. Emricasan (IDN-6556; Conatus Pharmaceuticals) is one of the drugs currently in Phase II, which will occupy more share in the therapeutic market of NASH as compared to two of the drugs in the Phase III, i.e. Cenicriviroc and Selonsertib.

It is expected that the NASH market size of currently available off-label therapies for the treatment shall decrease, owing to the launch of upcoming therapies in NASH market forecast period [2019-2028]. Moreover, the ratio of drugs that will target all the NASH stages (F1 to F4) to those that are restricted towards the treatment of only one-or two of the stages, will be significant. Overall, the increasing prevalence, awareness of the disease and promising emerging nonalcoholic steatohepatitis pipeline therapies will fuel the market size during the forecasted period of 2019-2028.

Request for Sample Pages

Nonalcoholic Steatohepatitis Report Insights

Nonalcoholic Steatohepatitis Patient Population

Nonalcoholic Steatohepatitis Therapeutic Approaches

NASH Pipeline Analysis

Nonalcoholic Steatohepatitis Market Size and Nonalcoholic Steatohepatitis Market Trends

NASH Market Opportunities

Impact of upcoming Nonalcoholic Steatohepatitis Therapies

Nonalcoholic Steatohepatitis Report Key Strengths

10 Years Nonalcoholic Steatohepatitis Forecast

NASH 7MM Coverage

Nonalcoholic Steatohepatitis Epidemiology Segmentation

Nonalcoholic Steatohepatitis Key Cross Competition

Nonalcoholic Steatohepatitis Market Size by Therapies

NASH Drugs Uptake

Nonalcoholic Steatohepatitis Report Assessment

NASH Pipeline Product Profiles

Nonalcoholic Steatohepatitis Key Products and Nonalcoholic Steatohepatitis Key Players

NASH Market Drivers and NASH Market Barriers

Key Benefits

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Nonalcoholic Steatohepatitis market

Organize NASH sales forecasting and marketing efforts by identifying the best opportunities for Nonalcoholic Steatohepatitis market

To understand the future market competition in the Nonalcoholic Steatohepatitis market.

Request for Sample Pages

Table of Contents

1. Key Insights

2. Non-Alcoholic Steatohepatitis (NASH) Market Overview at a Glance

2.1. Market Share (%) Distribution of NASH in 2016

2.2. Market Share (%) Distribution of NASH in 2028

3. Disease Background and Overview: Non-Alcoholic Steatohepatitis

3.1. Introduction

3.2. Signs and Symptoms of NASH

3.3. Causes and Risk Factors

3.4. Classification of NASH

3.5. Pathophysiology

3.5.1. Pathogenesis

3.5.2. Hedgehog signaling

3.6. Diagnosis

3.6.1. Physical examination

3.6.2. Laboratory examination

3.6.3. Blood tests

3.6.4. Imaging tests

3.6.5. Liver biopsy

3.6.6. Current diagnostic Trends (Noninvasive fibrosis tests)

3.6.7. Functional Diagnostic tools of NASH

4. Epidemiology and Patient Population

4.1. Key Findings

5. 7MM Epidemiology

5.1. Total Prevalent Cases of NAFLD in 7MM

5.2. Total Prevalent cases of NASH in 7MM

6. United States Epidemiology

6.1. Assumptions and Rationale

6.2. Total Prevalent Cases of NAFLD in the United States

6.3. Total Prevalent cases of NASH in the United States

6.4. NASH Segmentation by Fibrosis Stage in the United States

7. EU5 Epidemiology

7.1. Germany Epidemiology

7.1.1. Assumptions and Rationale

7.1.2. Total Prevalent Cases of NAFLD in Germany

7.1.3. Total Prevalent cases of NASH in Germany

7.1.4. NASH Segmentation by Fibrosis Stage in Germany

7.2. France Epidemiology

7.2.1. Assumptions and Rationale

7.2.2. Total Prevalent Cases of NAFLD in France

7.2.3. Total Prevalent cases of NASH in France

7.2.4. NASH Segmentation by Fibrosis Stage in France

7.3. Italy Epidemiology

7.3.1. Assumptions and Rationale

7.3.2. Total Prevalent Cases of NAFLD in Italy

7.3.3. Total Prevalent Cases of NASH in Italy

7.3.4. NASH Segmentation by Fibrosis Stage in Italy

7.4. Spain Epidemiology

7.4.1. Assumptions and Rationale

7.4.2. Total Prevalent Cases of NAFLD in Spain

7.4.3. Total Prevalent cases of NASH in Spain

7.4.4. NASH Segmentation by Fibrosis Stage in Spain

7.5. United Kingdom Epidemiology

7.5.1. Assumptions and Rationale

7.5.2. Total Prevalent Cases of NAFLD in the United Kingdom

7.5.3. Total Prevalent cases of NASH in the United Kingdom

7.5.4. NASH Segmentation by Fibrosis Stage in the United Kingdom

7.6. Japan Epidemiology

7.6.1. Assumptions and Rationale

7.6.2. Total Prevalent Cases of NAFLD in Japan

7.6.3. Total Prevalent cases of NASH in Japan

7.6.4. NASH Segmentation by Fibrosis Stage in Japan

8. Treatment Goals

9. Treatment Algorithm

10. Experts Opinions for Off-Label (Supportive Therapies) drugs for the treatment of NASH

11. Treatment Guidelines

11.1. American Association for the Study of Liver Diseases (AASLD) Current Recommendations for NAFLD/NASH

11.2. EASL–EASD–EASO* Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

11.3. Guideline for NAFLD/NASH, by the Japanese Society of Gastroenterology (JSG) in cooperation with “The Japan Society of Hepatology”

12. Unmet needs

13. Key Cross Competitors

14. Emerging Drugs

14.1. Elafibranor (GFT505): Genfit

14.1.1. Drug Description

14.1.2. Other Development Activities

14.1.3. Advantages & Disadvantages

14.1.4. Clinical Development

14.1.5. Clinical Trials Information

14.1.6. Safety and Efficacy

14.1.7. Product Profile

14.2. Obeticholic Acid (OCA, Ocaliva): Intercept Pharmaceuticals

14.2.1. Drug Description

14.2.2. Other Development Activities

14.2.3. Advantages & Disadvantages

14.2.4. Clinical Development

14.2.5. Clinical Trials Information

14.2.6. Safety and Efficacy

14.2.7. Product Profile

14.3. Selonsertib (SEL, Formerly GS-4997): Gilead Sciences

14.3.1. Drug Description

14.3.2. Other Development Activities

14.3.3. Advantages & Disadvantages

14.3.4. Clinical Development

14.3.5. Clinical Trials Information

14.3.6. Safety and Efficacy

14.3.7. Product Profile

14.4. Cenicriviroc (CVC): Allergan (Tobira Therapeutics)

14.4.1. Drug Description

14.4.2. Other Development Activities

14.4.3. Advantages and Disadvantages

14.4.4. Clinical Development

14.4.5. Clinical Trials Information

14.4.6. Safety and Efficacy

14.4.7. Product Profile

14.5. GS-9674: Gilead Sciences

14.5.1. Drug Description

14.5.2. Other Developmental Activities

14.5.3. Clinical Development

14.5.4. Clinical Trials Information

14.5.5. Safety and Efficacy

14.5.6. Product Profile

14.6. GS-0976: Gilead Sciences

14.6.1. Drug Description

14.6.2. Other Development Activities

14.6.3. Clinical Development

14.6.4. Clinical Trials Information

14.6.5. Safety and Efficacy

14.6.6. Product Profile

14.7. Aramchol_005: Galmed Pharmaceuticals Ltd.

14.7.1. Drug Description

14.7.2. Other Development Activities

14.7.3. Clinical Development

14.7.4. Clinical Trials Information

14.7.5. Safety and Efficacy

14.7.6. Product Profile

14.8. BMS-986036 (Pegylated FGF21): Bristol-Myers Squibb (BMS)

14.8.1. Drug Description

14.8.2. Other Development Activities

14.8.3. Clinical Development

14.8.4. Clinical Trials Information

14.8.5. Safety and Efficacy

14.8.6. Product Profile

14.9. IMM-124E: Immuron

14.9.1. Drug Description

14.9.2. Other Developmental Activities

14.9.3. Clinical Development

14.9.4. Clinical Trials Information

14.9.5. Safety and Efficacy

14.9.6. Product Profile

14.10. GR-MD-02: Galectin Therapeutics

14.10.1. Drug Description

14.10.2. Other Developmental Activities

14.10.3. Clinical Development

14.10.4. Clinical Trials Information

14.10.5. Safety and Efficacy

14.10.6. Product Profile

14.11. Emricasan (IDN-6556): Conatus Pharmaceuticals

14.11.1. Drug Description

14.11.2. Other Developmental Activities

14.11.3. Clinical Development

14.11.4. Clinical Trials Information

14.11.5. Safety and Efficacy

14.11.6. Product Profile

14.12. MSDC-0602K: Cirius Therapeutics

14.12.1. Drug Description

14.12.2. Other Developmental Activities

14.12.3. Clinical Development

14.12.4. Clinical Trials Information

14.12.5. Safety and Efficacy

14.12.6. Product Profile

14.13. NGM282: NGM Biopharmaceuticals

14.13.1. Drug Description

14.13.2. Other Developmental Activities

14.13.3. Clinical Development

14.13.4. Clinical Trials Information

14.13.5. Safety and Efficacy

14.13.6. Product Profile

14.14. JKB-121 (Nalmefene): TaiwanJ Pharmaceuticals

14.14.1. Drug Description

14.14.2. Other Developmental Activities

14.14.3. Clinical Development

14.14.4. Clinical Trials Information

14.14.5. Safety and Efficacy

14.14.6. Product Profile

14.15. Semaglutide: Novo Nordisk

14.15.1. Drug Description

14.15.2. Other Developmental Activities

14.15.3. Clinical Development

14.15.4. Clinical Trials Information

14.15.5. Product Profile

14.16. LMB763: Novartis Pharmaceuticals

14.16.1. Product Description

14.16.2. Other Developmental Activities

14.16.3. Clinical Development

14.16.4. Clinical Trials Information

14.16.5. Product Profile

14.17. LJN452 (Tropifexor): Novartis Pharmaceuticals

14.17.1. Drug Description

14.17.2. Other Developmental Activities

14.17.3. Clinical Development

14.17.4. Clinical Trials Information

14.17.5. Product Profile

14.18. MT-3995 (Apararenone): Mitsubishi Tanabe Pharma

14.18.1. Drug Description

14.18.2. Clinical Development

14.18.3. Clinical Trials Information

14.18.4. Product Profile

14.19. MN-001 (Tipelukast): MediciNova

14.19.1. Drug Description

14.19.2. Other Developmental Activities

14.19.3. Clinical Development

14.19.4. Clinical Trials Information

14.19.5. Safety and Efficacy

14.19.6. Product Profile

14.20. MGL-3196: Madrigal Pharmaceuticals

14.20.1. Drug Description

14.20.2. Other Developmental Activities

14.20.3. Clinical Development

14.20.4. Clinical Trials Information

14.20.5. Safety and Efficacy

14.20.6. Product Profile

14.21. Lanifibranor (IVA33): Inventiva Pharma

14.21.1. Drug Description

14.21.2. Other Developmental Activities

14.21.3. Clinical Development

14.21.4. Clinical Trials Information

14.21.5. Safety and Efficacy

14.21.6. Product Profile

14.22. Solithromycin (CEM-101): Cempra Inc (Melinta Therapeuctics)

14.22.1. Drug Description

14.22.2. Other Development Activities

14.22.3. Clinical Development

14.22.4. Clinical Trials Information

14.22.5. Safety and Efficacy

14.22.6. Product Profile

14.23. CF102 (Namodenoson): Can-Fite BioPharma

14.23.1. Drug Description

14.23.2. Other Developmental Activities

14.23.3. Clinical Development

14.23.4. Clinical Trials Information

14.23.5. Safety and Efficacy

14.23.6. Product Profile

15. Nonalcoholic Steatohepatitis (NASH): 7 Major Market Analysis

15.1. Key Findings

15.2. Market Size: Assumptions and Forecast Parameters

15.3. Market Size of Nonalcoholic Steatohepatitis (NASH) in 7MM

15.4. Market Distribution (%) of Nonalcoholic Steatohepatitis (NASH), in 2016, 2022 and 2028, in the 7MM

16. The United States: Market Outlook

16.1. The United States Market Size

16.1.1. Total Market size of NASH

16.1.2. Market Size of NASH by Therapies

17. EU5: Market Outlook

17.1. Germany Market Size

17.1.1. Total Market size of NASH

17.1.2. Market Size of NASH by Therapies

17.2. France Market Size

17.2.1. Total Market size of NASH

17.2.2. Market Size of NASH by Therapies

17.3. Italy Market Size

17.3.1. Total Market size of NASH

17.3.2. Market Size of NASH by Therapies

17.4. Spain Market Size

17.4.1. Total Market size of NASH

17.4.2. Market Size of NASH by Therapies

17.5. The United Kingdom Market Size

17.5.1. Total Market size of NASH

17.5.2. Market Size of NASH by Therapies

18. Japan: Market Outlook

18.1. Japan Market Size

18.1.1. Total Market size of NASH

18.1.2. Market Size of NASH by Therapies

19. Market Drivers

20. Market Barriers

21. Appendix

21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

#NASH Market #nash market share #nash market size #nash market research outlook #nash market report #nash #nonalcoholic steatohepatitis market #nonalcoholic steatohepatitis market share

0 notes

rajputdishank20-blog · 5 years ago

Text

Non-Alcoholic Steatohepatitis (NASH) Market By Drug Types, By Distribution Channels, By End-Users And Regions – Global Industry Analysis, Growth, Share, Size, Trends And Forecast 2020 – 2026

The global Non-Alcoholic Steatohepatitis (NASH) market is expected to reach USD 13.38 Billion by 2026, expanding at a CAGR 58.4% during the forecast period. The growth of this market is attributed to factors such as growing demand for ideal NASH therapeutics, surge in prevalence of NASH, and launch of pipeline drugs.

Non-alcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic or consume little alcohol. Non-alcoholic steatohepatitis (NASH) is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.

Market Trends, Drivers, Restraints, and Opportunities:

Increasing prevalence of severe chronic liver conditions including liver cirrhosis, liver cancer fuel the growth of market.

Change is lifestyle such as change in diet and exercise and increased consumption of alcohol propel the market.

Growing demand for ideal NASH therapeutics, surge in the prevalence of NASH, and expected launch of pipeline drugs during the forecast period boost the market growth.

Surging prevalence of diabetes and obesity and improvement in awareness of NASH in developing region fuel the market growth.

Government regulations supporting R&D activities for development of novel molecules is anticipated to fuel the market.

Poor diagnosis of the disease and lack of ideal diagnostic techniques hamper the market growth.

Significant burden to the public health system and unavailability of FDA-approved specifically tailored drugs for nonalcoholic steatohepatitis treatment hinder the market growth.

Factors such as complex pathophysiology, unknown etiology, and high cost of treatment restrain the growth of this market.

Read More: https://dataintelo.com/report/non-alcoholic-steatohepatitis-nash-market/

0 notes

sophiajhon-blog · 5 years ago

Text

Nonalcoholic Steatohepatitis Therapeutics Market Outlook and Growth Forecasted By 2024

A new market research report on the Global Nonalcoholic Steatohepatitis Therapeutics market has introduced by KD Market Insights. The report is dedicated to in-depth industry analysis of the global Nonalcoholic Steatohepatitis Therapeutics market. The Global Nonalcoholic Steatohepatitis Therapeutics analysis is broken down on different segmentation levels including Market By Drug Type. The global nonalcoholic steatohepatitis therapeutics market size is estimated to be USD XXX Million in 2018 and is expected to reach USD XXX Million by 2024, growing at a compound annual growth rate (CAGR) of XX.X% during the forecast period i.e., 2019-2024. Get Report Sample Copy @ https://www.kdmarketinsights.com/sample/5402 In the past years, the cases of people suffering from diabetes and obesity have increased at an alarming rate. In the North American region, there is a large population suffering from obesity and diabetes. Not only the adults but the children's are also considered to be suffering from obesity, which has increased almost three times compared to the past year. Due to which there is an increase in demand for treatment of such diseases, which is expected to propel the growth of nonalcoholic steatohepatitis therapeutics over the upcoming years. Nonalcoholic Steatohepatitis Therapeutics Market: Segmentation Analysis The nonalcoholic steatohepatitis therapeutics market is segmented by drug type. Based on drug type, the market is segmented into cenicriviroc, emricasan, elafibranor, ocaliva, selonsertib, and others, out of which, elafibranor segment is anticipated to grow at a significant CAGR over the forecast period i.e., 2019-2024. Further, it was followed by ocaliva segment in terms of market share in 2018. Nonalcoholic Steatohepatitis Therapeutics Market: Geographical Analysis Geographically, the report offers an analysis of North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In the nonalcoholic steatohepatitis therapeutics market, North America is anticipated to capture a notable market share in 2024. Further, factors such as rise in population suffering from obesity and diabetes in the region are expected to drive the growth of North America nonalcoholic steatohepatitis therapeutics market. Also, the North America market is driven on the back of prevailing cases of high cholesterol and is projected to grow at a noteworthy compound annual growth rate (CAGR) from 2019 to 2024. Nonalcoholic Steatohepatitis Therapeutics Market: Competitive Analysis The report also covers detailed competitive analysis of major market players of global nonalcoholic steatohepatitis therapeutics market, such as GENFIT SA, Gilead Sciences, Inc., Immuron Ltd., Astrazeneca Plc, Conatus Pharmaceuticals, Tobira Therapeutics, Inc., Zydus Cadila, Galmed Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Novo Nordisk A/S and other major & niche players. The global nonalcoholic steatohepatitis therapeutics market is witnessing a wide range of industry activities such as product launch, acquisition, partnership, and expansion across the globe. Segmentation By Drug Type: - Cenicriviroc - Emricasan - Elafibranor - Ocaliva - Selonsertib - Others By Geography: - North America (U.S. & Canada) - Europe (Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe) - Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand and Rest of Asia Pacific) - Latin America (Brazil, Mexico, and Rest of Latin America) - Middle East & Africa (GCC, North Africa, South Africa and Rest of Middle East & Africa) Competitive Landscape The report profiles various major market players such as • GENFIT SA • Gilead Sciences, Inc. • Immuron Ltd. • Astrazeneca Plc • Conatus Pharmaceuticals • Tobira Therapeutics, Inc. • Zydus Cadila • Galmed Pharmaceuticals Ltd. • Intercept Pharmaceuticals Inc. • Novo Nordisk A/S • Other Major & Niche Players Access Complete Research Report with TOC @ https://www.kdmarketinsights.com/product/nonalcoholic-steatohepatitis-therapeutics-market Table of Content Research Methodology Market Definition and List of Abbreviations 1. Executive Summary 2. Growth Drivers & Barriers in Global Nonalcoholic Steatohepatitis Therapeutics Market 3. Global Nonalcoholic Steatohepatitis Therapeutics Market Trends 4. Opportunities in Global Nonalcoholic Steatohepatitis Therapeutics Market 5. Recent Industry Activities 6. Porter's Five Forces Analysis 7. Market Value Chain Analysis 8. Global Nonalcoholic Steatohepatitis Therapeutics Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 9. Global Nonalcoholic Steatohepatitis Therapeutics Market Segmentation Analysis, By Drug Type 9.1. Introduction 9.2. Market Attractiveness, By Drug Type 9.3. BPS Analysis, By Drug Type 9.4. Cenicriviroc Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 9.5. Emricasan Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 9.6. Elafibranor Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 9.7. Ocaliva Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 9.8. Selonsertib Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 9.9. Others Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10. Geographical Analysis 10.1. Introduction 10.2. North America Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.2.1. By Drug Type 10.2.1.1. Introduction 10.2.1.2. Market Attractiveness, By Drug Type 10.2.1.3. BPS Analysis, By Drug Type 10.2.1.4. Cenicriviroc Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.2.1.5. Emricasan Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.2.1.6. Elafibranor Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.2.1.7. Ocaliva Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.2.1.8. Selonsertib Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.2.1.9. Others Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.2.2. By Country 10.2.2.1. Introduction 10.2.2.2. Market Attractiveness, By Country 10.2.2.3. BPS Analysis, By Country 10.2.2.4. U.S. Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.2.2.5. Canada Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.3. Europe Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.3.1. By Drug Type 10.3.1.1. Introduction 10.3.1.2. Market Attractiveness, By Drug Type 10.3.1.3. BPS Analysis, By Drug Type 10.3.1.4. Cenicriviroc Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.3.1.5. Emricasan Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.3.1.6. Elafibranor Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.3.1.7. Ocaliva Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.3.1.8. Selonsertib Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.3.1.9. Others Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.3.2. By Country 10.3.2.1. Introduction 10.3.2.2. Market Attractiveness, By Country 10.3.2.3. BPS Analysis, By Country 10.3.2.4. Germany Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.3.2.5. United Kingdom Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.3.2.6. France Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.3.2.7. Italy Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.3.2.8. Spain Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.3.2.9. Russia Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.3.2.10. Rest of Europe Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.4. Asia Pacific Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.4.1. By Drug Type 10.4.1.1. Introduction 10.4.1.2. Market Attractiveness, By Drug Type 10.4.1.3. BPS Analysis, By Drug Type 10.4.1.4. Cenicriviroc Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.4.1.5. Emricasan Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.4.1.6. Elafibranor Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.4.1.7. Ocaliva Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.4.1.8. Selonsertib Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.4.1.9. Others Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.4.2. By Country 10.4.2.1. Introduction 10.4.2.2. Market Attractiveness, By Country 10.4.2.3. BPS Analysis, By Country 10.4.2.4. China Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.4.2.5. India Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.4.2.6. Japan Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.4.2.7. Australia Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.4.2.8. South Korea Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.4.2.9. Indonesia Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.4.2.10. Thailand Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.4.2.11. New Zealand Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.4.2.12. Rest of Asia Pacific Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.5. Latin America Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.5.1. By Drug Type 10.5.1.1. Introduction 10.5.1.2. Market Attractiveness, By Drug Type 10.5.1.3. BPS Analysis, By Drug Type 10.5.1.4. Cenicriviroc Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.5.1.5. Emricasan Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.5.1.6. Elafibranor Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.5.1.7. Ocaliva Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.5.1.8. Selonsertib Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.5.1.9. Others Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.5.2. By Country 10.5.2.1. Introduction 10.5.2.2. Market Attractiveness, By Country 10.5.2.3. BPS Analysis, By Country 10.5.2.4. Brazil Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.5.2.5. Mexico Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.5.2.6. Rest of Latin America Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.6. The Middle East & Africa Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.6.1. By Drug Type 10.6.1.1. Introduction 10.6.1.2. Market Attractiveness, By Drug Type 10.6.1.3. BPS Analysis, By Drug Type 10.6.1.4. Cenicriviroc Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.6.1.5. Emricasan Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.6.1.6. Elafibranor Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.6.1.7. Ocaliva Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.6.1.8. Selonsertib Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.6.1.9. Others Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.6.2. By Geography 10.6.2.1. Introduction 10.6.2.2. Market Attractiveness, By Geography 10.6.2.3. BPS Analysis, By Geography 10.6.2.4. GCC Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.6.2.5. North Africa Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.6.2.6. South Africa Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 10.6.2.7. Rest of Middle East & Africa Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024 Continue @... Check for Discount @ https://www.kdmarketinsights.com/discount/5402 About Us: KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market. Contact Us: KD Market Insights 150 State Street, Albany, New York, USA 12207 +1 (518) 300-1215 Email: [email protected] Website: www.kdmarketinsights.com https://marketreserachtab.blogspot.com/ http://kdmarketinsights.blogspot.com/

#Nonalcoholic Steatohepatitis Therapeutics Market #Nonalcoholic Steatohepatitis Therapeutics Market Size #Nonalcoholic Steatohepatitis Therapeutics Market Share

0 notes

azveille · 6 years ago

Text

Conatus wields ax as Novartis-partnered NASH drug fails again

A phase 2b trial of Conatus Pharmaceuticals’ emricasan in nonalcoholic steatohepatitis (NASH) has missed its primary endpoint. The latest setback prompted Novartis-partnered Conatus to lay off40% of its staff and begin looking for strategic alternatives.

Novartis catapulted Conatus into the limelight in 2016 when it paid $50 million for an option on oral pan-caspase inhibitor emricasan. Since then, emricasan has advanced through a series of readouts that have suggested it poses little threat to the other companies pursuing NASH, culminating in the delivery of data from the phase 2b ENCORE-LF trial.

Neither dose of emricasan outperformed placebo against a primary endpoint that looked at whether patients died, suffered new decompensation events or experienced liver disease progression. There were “no clear trends indicating a potential treatment effect,” Conatus said in a statement.

To compound the failure, Conatus revealed a 24-week extension to one of its four midphase flops also missed the mark. Conatus said the data from the extension were consistent with results from the original 24-week study, which found emricasan was no better than placebo at improving mean hepatic venous pressure gradient in compensated NASH cirrhosis patients.

As it navigated the series of setbacks, Conatus highlighted positives and looked to future trials to generate stronger evidence. But the biotech has now come to the end of the road, with CEO Steven Mento accepting the trials “provided a fair evaluation of emricasan’s lack of efficacy.”

With multiple failed trials to its name, Conatus is set to lay off 40% of its staff, suspend development of preclinical-stage caspase-1 inhibitor CTS-2090 and engage Oppenheimer & Co. to look into strategic alternatives that enable its beleaguered investors to make some money back. Through the changes, Conatus thinks it can end 2019 with up to $15 million in cash, equivalents and marketable securities, buying it the time to search for a way out of its current predicament.

The repeat failures of emricasan have left Conatus with little to offer a potential buyer. Beyond its Nasdaq listing, Conatus’ main asset is CTS-2090. Mento talked up the drug in a release to disclose the reorganization.

“We remain excited by the potential of CTS-2090 as a uniquely positioned inflammasome disease compound,” Mento said. “Although we are halting development activities for CTS-2090, we plan to continue to explore a variety of opportunities to advance this compound.”

0 notes

healthcaretrends-blog · 6 years ago

Text

Liver Fibrosis Treatment Market Study 2019: Impressively growing Opportunities

Liver fibrosis is characterized by repeated or continuous damage to liver resulting in an abnormally large amount of scar tissue in the liver. Fibrosis does not show any symptoms, however severe scarring results into cirrhosis, which further leads to cause symptoms. To detect the severity of disease, healthcare professionals conduct blood and imaging test, followed by liver biopsy, if required. In the possible treatment options for liver fibrosis, healthcare professionals focus on treating the cause, which often stops and slowdowns further scarring of liver and results in improvement of condition. The possible treatment options for liver fibrosis include use of antiviral drugs, removal or dissolve of a blockage in the bile ducts, lifestyle changes such as lower consumption of alcohol, control regime for obesity and overweight, and controlling blood sugar & lipid levels in people with nonalcoholic fatty liver.

Furthermore, research funding by various private research organizations to conduct research related to development of treatment for liver fibrosis and other fatty liver disease is expected to spur growth of liver fibrosis treatment market. For instance, in August 2018; professor from College of Science at Virginia Tech and Department of Pharmacology at the University of Virginia received US$ 400,000 grant from the Virginia Biosciences Health Research Corporation (VBHRC) with US$ 800,000 matching funds from Continuum Biosciences, Inc. This grant along with matching funds will help researchers to develop drugs to treat nonalcoholic steatohepatitis (NASH).

The global liver fibrosis treatment market size is expected to witness a CAGR of 10.8% over the forecast period (2018 – 2026) reaching a value of US$ 28.1 billion in 2026.

Request A Sample Copy Of This Report:

https://www.coherentmarketinsights.com/insight/request-sample/2320

Liver fibrosis results from various chronic injuries and it often progresses to liver cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. Moreover, liver transplantation is only treatment available for advanced stage liver fibrosis. Therefore, new treatment strategies are currently in clinical development stages to treat the liver fibrosis. These treatment option include inhibition of hepatic injury, inhibition of activation of Hematopoietic Stem Cells (HSCs), and inhibition of proliferation of HSCs, inhibition of deposition of type I collagen and proliferation of HSCs. Treatment options for liver fibrosis are usually depends on the underlying cause of the fibrosis. A healthcare professional can treat the underlying liver fibrosis illness conditions, to reduce the effects of liver disease.

Furthermore, key players in the liver fibrosis treatment market are engaged in pre-clinical and clinical studies to develop novel treatment therapies in liver fibrosis regime. For instance, in March 2018, the U.S. FDA granted Orphan Drug Designation for PTG-300: a subcutaneous injectable developed by Protagonist Therapeutics, Inc. The PTG-300 is currently in clinical development stage for the potential treatment of beta-thalassemia, and can also be used in the liver fibrosis treatment.

For instance, Gilead Sciences, Inc., in October 2017, released the Phase II result studies for Selonsertib: GS-0976 in Nonalcoholic Steatohepatitis (NASH) stage F3 liver fibrosis. These studies reported that, GS-0976 led to significant reductions in concentration of liver fat and fibrosis. Moreover, Gilead Sciences also contain 18 other pipeline molecules in the liver fibrosis treatment, which is further expected to boost company’s revenue in near future.In April 2017, Tobira Therapeutics, Inc. initiated the clinical study to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult patients with NASH. The study is expected to complete in July 2019.

In April 2017, Bristol-Myers Squibb Company presented the Phase II clinical trial study of BMS-986036: a human fibroblast growth factor. The study results reported that BMS-986036 shows consistent improvement in liver fat, liver injury, and liver fibrosis in patients with Nonalcoholic Steatohepatitis (NASH). Increasing number of clinical trials are currently in process for the treatment of liver fibrosis, which are expected to augment the market growth over the forecast period.

Click To Reading More On Liver Fibrosis Treatment Market

About Coherent Market Insights:

Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected]

#Liver Fibrosis Treatment Market

0 notes